

























Prevention of colorectal cancer by colonoscopic surveillance in families
with hereditary colorectal cancer
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Abstract
Objective. In recent years persons at risk for colorectal cancers (CRC) have been subjected to follow-up with colonoscopy
in many centres. There is, however, limited knowledge about the effect of such interventions. The objective of this study was
to report the results of our observations during the past 15 years. Material and methods. Healthy persons were included
in the study according to their family history of CRCs, and prospectively followed with colonoscopies. Results. Altogether,
1133 individuals were included and observed for a total of 3474 follow-up years from the first to the last colonoscopy
initiated by our activity. Mismatch repair (MMR) mutations were detected in 6.5% of cases. A total of 1383 polyps were
removed, 72% were less than 5 mm in diameter. Findings were scored as hyperplastic polyps (n/887), adenomas with mild
to moderate dysplasia (n/460), adenomas with high-grade dysplasia (n/30) and cancers (n/6). Two cancers were
observed after the first colonoscopy, compared with 2.6 expected by chance and more than 20 expected under the
hypothesis of predominant inherited diseases in the families. Observed annual incidence rates for adenomas were similar in
all groups, while in the mutation carriers there was a higher frequency of progression to severe dysplasia or infiltrating
cancer. Conclusions. A simple explanation for the combined findings may be that all selected families had a similar
tendency to produce adenomas, while mutation carriers more frequently demonstrated dysplasia/cancer in the adenomas.
The low annual incidence rates for CRC indicated that the removal of adenomas may have prevented cancers.
Key Words: Adenomas, colonoscopy, colorectal cancer, HNPCC, incidence, MMR mutations, polyps, prevention,
prospective, surveillance
Introduction
Colorectal cancer (CRC) is the most common
cancer among men and women in Norway [1].
About 10% of colorectal cancers may be inherited
[2]. Individuals belonging to families where cancers
previously have occurred have an increased risk of
developing cancer; they may develop cancer at a
young age (3040 years) and have an increased risk
of having multiple primaries [35].
Colorectal adenomas are known to be the pre-
cursors of sporadic and hereditary CRC [6,7].
Several studies have shown that removal of adeno-
mas may reduce the incidence of CRC [810].
Because CRC can be cured by early diagnosis and
treatment [8], it has become a challenge to identify
those at risk, and to subject them to early diagnosis
and treatment. An accurate history of cancer in the
family is the initial tool in identifying persons at risk.
A family history of cancer may, per se , provide the
rationale for follow-up, and it is the starting-point for
mutation testing.
If no cellular dysplasia is visible in the microscope,
a polyp is scored as hyperplastic [11]. Rijcken et al.
[12] have shown that it seems unlikely that hyper-
plastic polyps are precursors for cancers in patients
with hereditary non-polyposis cancer coli
(HNPCC).
Two to six percent of CRCs are caused by germ-
line mutations in the mismatch repair (MMR) genes
MLH1, MSH2, MSH6, PMS1 and PMS2 [1316].
The genes encode protein products that recognize
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and correct errors that arise when DNA is replicated
[13,17]. Mutation carriers develop intestinal polyps
at about the same frequency as the general popula-
tion, but at a younger age [18]. The adenomas are
more likely to undergo malignant transformation
and to display an accelerated adenoma to carcinoma
transition as compared to the adenomas seen in the
general population [19,20]. In HNPCC, the pro-
gression from adenoma to carcinoma may take
B/3 years [18,20]. In sporadic cancer this progres-
sion takes approximately 1015 years [21]. Distal
cancers are suggested to be related more to environ-
mental factors and proximal cancers, usually geneti-
cally caused [22]. In general, there seems to be an
increasing prevalence of proximal cancers with
increasing age [2325].
We have been inviting cancer kindred to our
outpatient cancer genetic clinic since 1989, and
have offered follow-up by colonoscopy to members
of CRC families. The aim of this prospective study
was to evaluate the results of screening with respect
to tumours demonstrated and annual incidence of
adenomas and cancers, stratified on clinical classifi-
cation of the families and on results of mutation
testing.
Material and methods
The patients included in the study had been referred
to the Section of Genetic counselling, Rikshospita-
let-Radiumhospitalet, from 1989 to spring 2005.
They were included according to their family history
of colorectal- and other cancers applying wide
clinical criteria [26]. The family history was ex-
panded and information on the site and classification
of cancers and polyps and age at diagnosis were
obtained and verified in the medical files and/or in
The National Cancer Registry, whenever possible.
Patients with familial adenomatous polyposis and
other well-defined cancer syndromes were excluded.
The remaining CRC families were classified accord-
ing to the following criteria:
I. Mutation positive: Any family with a detected
mutation in one of the MMR genes MLH1, MSH2
or MSH6. (PMS1 and PMS2 were not tested).
II. HNPCC: At least three relatives in two successive
generations with histologically verified adenocarci-
noma in the colon, rectum, endometrium, duode-
num, ureter or pelvis, and at least one being diagnosed
at B/50 years of age (Amsterdam criteria II) [27], but
without any mutation being demonstrated.
III. HNPCC-like: Families not meeting the above
criteria, but meeting the Amsterdam criteria if other
HNPCC-related cancers such as cancer of the sto-
mach, hepatobiliary tract, pancreas or ovarium are
scored as affected in addition to CRC, or families
meeting the Amsterdam criteria but with one skipped
generation.
IV. Late-onset hereditary gastrointestinal cancer
(LOCRC): Families not meeting the above criteria,
but with four or more gastric- or colorectal cancers in
one lineage, all diagnosed at over 50 years of age [28],
and skipped generations allowed for. One of the four
may be other HNPCC-related cancers.
Mutation testing
When mutation testing became available, those
affected were examined as previously reported
[29,30]. When a mutation was found, the healthy
family members were offered predictive testing and
those not carrying the family mutation were ex-
cluded from further follow-up. Owing to lack of
resources, mutation analyses have not been per-
formed in all families.
Colonoscopy
In the selected families, all patients considered to be
cured of CRC and/or other HNPCC-related cancers
and all 1st degree relatives of the cancer patients
were offered surveillance by colonoscopy from age
35 years on. From 1989 to 1996 colonoscopy every
third year was recommended. From 1997 onwards
we followed the ICG-HNPCC guidelines [31] and
offered colonoscopy every two years from 25 to 30
years of age in HNPCC and HNPCC-like kindred,
and every fifth year from age 40 years on in LOCRC
[28]. Whenever a tubular adenoma was demon-
strated, the next colonoscopy was recommended
within one year. If the finding was a CRC, a villous
adenoma, a tubulovillous adenoma or an adenoma
with grave dysplasia, the gastroenterologist could
schedule additional intervention. The screening was
nation-wide as the colonoscopies were performed at
the patients’ local hospitals.
Number of cancers expected to occur by chance
The number of infiltrating CRCs expected to occur
by chance was estimated based on population annual
incidence rates [1] with respect to age, gender and
follow-up time for each person controlled. The
calculations were done twice; once when considering
age for the whole observation period to be the age at
the first control, the other using age at the last
control, and the result was estimated as the mean of
the two.
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Database and statistics
All data were kept in our computerized medical file
using an Oracle# database and a dBase Plus#
application. The database was analysed using
TOAD# and statistical tests performed by Sy-
stat10# and StatXact5#.
Ethics
Permission to access the medical files for informa-
tion was obtained in writing from all living persons,
and from the relatives of the deceased. Written
informed consent underlay all requests for tumour
specimens and genetic testing. All activities reported
were approved by the government, under health
care. All information was kept in our medical files.
No results identifying any individual patient were
exported from the medical files. No research registry
was set up. All activities complied with national
legislation and included genetic counselling of every
person participating in the study.
Findings
Polyps were removed and classified by a pathologist.
The histopathological scores were copied from the
medical files for the present study. Results were
scored as normal, hyperplastic polyp, adenoma with
low-grade dysplasia (/adenoma I) or moderate-
grade dysplasia (/adenoma II) or high-grade dys-
plasia with the pathologist’s discussion excluding
invasive cancer (/adenoma III) or adenocarcinoma
in the colon/rectum (/cancer). Information was
noted when obtainable on size and various histo-
pathological subtypes. Location of a finding was
scored as proximal (including the caecum, ascending
and transverse colon), the distal (including the
descending and sigmoid colon) and rectum.
Results
In all, 1133 individuals from 398 families were
included in the study. The total number of years of
follow-up was 3474 and a total of 2748 colonosco-
pies were performed; 715 persons had been exam-
ined twice or more times. For details, see Table I.
Number of findings/annual incidences
Including the first control, the total number of
findings amounted to 1383; hyperplastic polyps/
887, adenomas I/II/460, adenomas III/30 and
cancers/6. Forty-six percent of the adenomas I/II,
80% of the adenomas III and 67% of the cancers
were found during the first control. Findings at
follow-up and calculated annual incidence rates are
summarized in Table II.
The number of cancers expected to occur by
chance was 2.6 compared with 2 cancers found at
follow-up examinations. Assuming a 2% annual
incidence rate of cancer in MMR mutation carriers,
an annual incidence rate of about 1% in 1st degree
relatives of those affected could be expected in
HNPCC kindred. This being the case, we observed
1 cancer and expected 16 in the HNPCC group
(x2/14.4, pB/0.05), and we observed 1 cancer
and expected 6 in the mutation carriers (x/4.2,
pB/0.5), and the one cancer was cured.
Taking the life-time risk for cancer to be the
observed annual incidence rates/the 40 years at
risk, we arrived at an estimated life-time risk for
CRC inside our health-care programme to be 0% in
LOCRC, 0.0006/40/2.4% in HNPCC and
0.003/40/12% in mutation carriers  all of which
are considerably below the expected rates.
Grouping the findings at follow-up as cancer or
severely dysplastic adenomas, compared to total
number of adenomas and cancers, the findings
were 1/60/1.7% for LOCRC, 3/118/2.5% for
HNPCC and 4/23/17.4% for mutation carriers
(Table II), resulting in a two-sided Fisher exact
p-value of 0.014 for mutation-positive compared to
HNPCC, 0.02 for mutation-positive compared
to LOCRC and 1.00 for HNPCC compared to
LOCRC.
The total findings according to family history
are listed in Tables III and IV. The total number
of findings per person is not included, but the
Table I. Number of colonoscopies and follow-up years.
Ascertainment Mut. carriers HNPCC HNPCC-like LO CRC Total
Families included in the study and follow-up
Number of persons 73 528 186 346 1133
Number of families 24 158 75 165 398
Number of colonoscopies 220 1342 559 627 2748
Total years of follow-up 302 1630 798 744 3474
Median follow-up time (range) 4.3 (115.2) 4.1 (0.215.2) 4.9 (0.314.2) 4.9 (012.6)
Median age 1.control (range) 48.8 (22.475.9) 45.2 (19.880.2) 40.3 (20.468.9) 47.9 (27.582.6)
Abbreviations: HNPCC/hereditary non-polyposis cancer coli; LOCRC/late-onset gastrointestinal cancer.
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distributions fit the expectations if the polyps were
randomly or multifactorially caused, but with two
exceptions: 1) A limited number (n/6) demon-
strated ]/20 hyperplastic polyps. Three of them
belonged to LOCRC families, and three were in
HNPCC kindred, among whom none were verified
as mutation carriers. 2) One patient harboured 14
adenomas III and 1519 TAI/II. This patient had
been investigated for mutations in the APC and
MYH genes, but the findings were normal. The
family was classified as HNPCC-like, because of
other HNPCC-related cancers in the family.
Description of polyps
Details are shown in Tables III and IV.
Size was measured in 79% (1089/1377) of all
polyps. Seventy-two percent (71.6) (780/1089) were
B/5 mm. Among the six cancers, size was unknown
in three, and 6 mm, 15 mm and 30 mm, respectively,
in the remaining three.
Of the adenomas that were graded, 195 of the
tubular adenomas, 28 of the tubulovillous adeno-
mas, 1 villous and 1 flat adenoma all showed
moderate dysplasia, while the remainder (including
4 adenomas of unknown pattern) showed mild
dysplasia. Six and a half (6.4) percent (73/1133) of
the participants were mutation carriers. Almost 6%
(5.7) (24/419) of the tubular adenomas and 18%
(8/44) of the tubulovillous adenomas belonged to
mutation carriers.
HNPCC-, HNPCC-like- and LOCRC families all
showed the same distribution of hyperplastic polyps
and adenomas I/II throughout the colon, while half
of the adenomas III and 2/3 of the cancers were
located in the proximal colon. Mutation carriers
were different. Fifty-three percent of the hyperplastic
polyps and 35% of the adenomas I/II were located in
the rectum, while four of the proximal adenomas I/II
and both of the proximal adenomas III were located
in the caecum.
Characteristics of the cancers
Of the six cancers detected, four were located in the
proximal colon, one in the distal colon and one in
the rectum (Table IV). Median age at cancer
diagnosis was 57.5 years (4371 years).
Two cancers were detected at follow-up. One
patient had previously had a colon cancer at the
age of 44 years and a second colon cancer at 46 years
of age. The patient still had part of the colon left,
and at follow-up, at 53 years of age, two years after a
normal colonoscopy, a third colon cancer was
Table II. Annual incidence rates of findings according to family history (number of findings in follow-up controls).
Family class Hyperplastic polyps Adenomas I/II Adenomas III Cancers
Mut. carriers 0.109 (33) 0.063 (19) 0.01 (3) 0.003 (1)
HNPCC 0.169 (275) 0.071 (115) 0.0012 (2) 0.0006 (1)
HNPCC-like 0.123 (98) 0.069 (55) 0 0
LOCRC 0.195 (145) 0.079 (59) 0.001 (1) 0
Total 0.159 (551) 0.071 (248) 0.0017 (6) 0.0066 (2)
Abbreviations: HNPCC/hereditary non-polyposis cancer coli; LOCRC/late-onset gastrointestinal cancer.
Table III. Number of hyperplastic polyps according to family history, location and size.
Hyperplastic polyps Mut. carriers HNPCC HNPCC-like LOCRC Total
Findings at 1st control 14 151 60 111 336
Findings at follow-up 33 275 98 145 551
Location
Proximal colon 8 (17%) 137 (32.2%) 59 (37.3%) 81 (31.6%) 285 (32.1%)
Distal colon 11 (23.4%) 140 (32.9%) 52 (32.9%) 102 (39.8%) 305 (34.4%)
Rectal colon 25 (53.2%) 131 (30.8%) 40 (25.3%) 62 (24.2%) 258 (29.1%)
Unknown 3 (6.4%) 18 (4.2%) 7 (4.4%) 11 (4.3%) 39 (4.4%)
Total 47 (100%) 426 (100%) 158 (100%) 256 (100%) 887 (100%)
Size
0104 mm 28 276 91 156 551
0509 mm 3 51 21 46 121
1019 mm 1 5 5 5 16
20 // mm 0 10 2 0 12
Unknown 15 84 39 49 187
Abbreviations: HNPCC/hereditary non-polyposis cancer coli; LOCRC/late-onset gastrointestinal cancer.
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Table IV. Numbers of adenomas I/II/III and cancers according to family history, location, size, form and histology.
Mut. carriers HNPCC HNPCC-like LOCRC Total
Tubular adenomas I/II
Findings at 1st control 10 95 51 56 212
Findings at follow-up 19 115 55 59 248
Location
Proximal colon 10 (34.5%)1 82 (39.1%) 42 (39.6%) 47 (40.9%) 181 (39.3%)
Distal colon 6 (20.7%) 90 (42.3%) 41 (38.7%) 39 (33.9%) 176 (38.3%)
Rectal colon 10 (34.5%) 30 (14.3%) 16 (15.1%) 19 (16.5%) 75 (16.3%)
Unknown 3 (10.3%) 8 (3.8%) 7 (6.6%) 10 (8.7%) 28 (6.1%)
Total 29 (100%) 210 (100%) 106 (100%) 115 (100%) 460 (100%)
Size
0104 mm 15 118 46 48 227
0509 mm 4 46 31 29 110
1019 mm 4 8 3 7 22
20// mm 0 3 0 2 5
Unknown 6 35 26 29 96
Form
Tubular 22 168 101 104 395
Tubulovillous 5 21 2 11 39
Villous 0 1 0 0 1
Serrated 1 1 0 0 2
Flat 0 1 0 0 1
Unknown 1 18 3 0 22
Histology
Low grade 11 93 35 53 192
Moderate grade 15 87 64 59 225
Unknown 3 30 7 3 43
Tubular adenomas III
Findings at 1st control 2 3 14 5 24
Findings at follow-up 3 2 0 1 6
Location
Proximal colon 22 1 93 3 15
Distal colon 3 3 33 3 12
Rectal colon 0 1 23 0 3
Total 5 5 14 6 30
Size
0104 mm 0 2 0 0 2
0509 mm 3 0 14 2 19
1019 m 1 1 0 2 4
20// mm 0 0 0 0 0
Unknown 1 2 0 2 5
Form
Tubular 2 3 13 6 24
Tubulovillous 3 1 1 0 5
Unknown 0 1 0 0 1
Histology
High grade 5 5 14 6 30
Cancers
Findings at 1st control 0 2 0 2 4
Findings at follow-up 1 1 0 0 2
Location
Proximal colon 1 24 0 1 4
Distal colon 0 1 0 0 1
Rectal colon 0 0 0 1 1
Abbreviations: HNPCC/hereditary non-polyposis cancer coli; LOCRC/late-onset gastrointestinal cancer.
Adenomas I/low-grade dysplasia; II/moderate-grade dysplasia; III/high-grade dysplasia; cancers/adenocarcinomas.
1Four located in the caecum; 2both located in the caecum; 3all the adenomas were found at first control in one patient; 4one located in the
caecum.
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detected. At this point he underwent a total colect-
omy. He belonged to a HNPCC family, and later we
demonstrated an MSH2 mutation. Thirteen years
have now passed and the patient is healthy. The
other patient had a tubular adenoma in the sigmoi-
deum and a histologically normal biopsy taken from
a thickening of the caecal mucosa at her first
colonoscopy at 58 years of age. Two months later
the patient underwent surgery to remove her uterus
and ovaries because of descensus of the uterus.
Metastases were found in one of her ovaries. The
primary focus of the cancer was a low differentiated
adenocarcinoma from the location where the normal
biopsy had been taken two months earlier. After
three years, the patient died of her cancer. Her
family met the Amsterdam II criteria because one
young family member had an endometrial tumour.
One affected obligate carrier has been sequenced for
MLH1, MSH2 and MSH6 without detection of
mutation.
Discussion
We observed no more cancers than was expected by
chance alone, 2 compared with 2.6. The low annual
incidence rate for cancer in HNPCC kindred and in
MMR mutation carriers conflicts with the reported
penetrance for the mutations in question [32,33].
Obviously, the number of events was limited for
these forms of calculations, but in all the ways we
analysed the figures, we arrived at the conclusion
that our intervention may have prevented CRC by
removing adenomas. The estimated life-time risks
in the subgroups were planned and carried out
despite the low numbers of cancers found. The
finding was the low numbers of cancers, which in
turn invalidated the calculations because of the low
numbers.
We demonstrated an annual incidence rate of
256/3474/7.4% of adenomas (including cancers),
and there was no difference between HNPCC and
LOCRC kindred. In the mutation carriers, however,
the adenomas more frequently had progressed to
severe dysplasia or cancer. The adenomas appeared
to be randomly distributed between the persons
examined. The hyperplastic polyps had a similar
distribution, but with an excess of persons with more
than 20 polyps. The observation was that the
demonstrated MMR mutation carriers did not have
increased annual incidence rates of adenomas com-
pared with all the members of HNPCC and/or
LOCRC kindred.
Our findings are in keeping with the notion that all
kindred were demonstrated to have a similar annual
incidence rate of polyps, and in the mutation
carriers/HNPCC kindred the adenomas progressed
more rapidly to carcinomas. This has also been
suggested by Vasen et al. [18], and we found the
material insufficient to allow further speculatation.
Findings in all groups were distributed throughout
the colon, making it appropriate to continue recom-
mending full colonoscopic surveillance. In mutation
carriers/HNPCC, colonoscopic surveillance every
two years if the colon is clear, as recommended
[31], seems reasonable. The genetic basis of
LOCRC is unknown. In our study no cancers were
detected at follow-up, and the adenoma-carcinoma
sequence is not thought to be accelerated. Five-year
intervals of colonoscopy if the colon is clear, as
suggested by others, should be appropriate [34,35].
One of the strengths of our study was the nation-
wide selection of CRC families, and the large
number of persons at risk included. A limitation
was the low prevalence of mutation carriers demon-
strated, but this probably reflected a low prevalence
in our population. The low number of cancers
demonstrated, and the low power of demonstrating
a protective effect of an intervention, is a general
problem in studies of this kind and not a limitation
specific to our study. This problem calls for broad
collaborative studies in order to arrive at more
definite conclusions.
In conclusion, we observed that the families
selected by family history of CRC prospectively
produced adenomas. Our findings support the no-
tion that the adenoma formation has a separate
mechanism, while MMR mutation carriers have a
rapid progression from adenoma to carcinoma once
an adenoma is established. Our intervention may
have prevented cancers, as demonstrated by the low
annual incidence rate observed compared with
expectations based on retrospective reports in similar
kindred, and the one cancer found at follow-up in a
mutation carrier was cured.
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